Lacaba, Jennifer L.
HRN: 25-35-19 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/27/2024
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
06/27/2024
07/04/2024
IVTT
2.25
Q6H
Cholangitis
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes